RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Robert Kirken to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications Robert Kirken has written about Drug Resistance, Neoplasm.
Robert Kirken
Connection Strength
0.484
Drug Resistance, Neoplasm
  1. Oaxaca DM, Yang-Reid SA, Ross JA, Rodriguez G, Staniswalis JG, Kirken RA. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Tumour Biol. 2016 Sep; 37(9):12643-12654.
    View in: PubMed
    Score: 0.484
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support